Related Experiment Video
Updated: Aug 2, 2026

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients
L Salauze1, C van der Velden, I Lagroye
1Laboratoire PIOM, ENSCPB-EPHE, Pessac, France.
Abstract:
Amyotrophic lateral sclerosis (ALS) is a degenerative disease of unknown aetiology, affecting motor neurons. Many radical species, such as O(2)(-) NO, and ONOO(-), and lipoperoxidative products are involved, but not all processes have yet been identified. It is known that the oxidation of catecholamines leads to quinone formation. These orthoquinones react with the sulphhydril group of cysteine to produce neurotoxic cysteinyl catecholamine (Cyst-CA) neo-compounds. We synthesised Cyst-CA in order to mimic their endogenous formation. Using the ELISA method, circulating antibodies to Cyst-CA were found in sporadic ALS sera. First, the antibody titres were compared to those of controls and patients with other neurodegenerative diseases. Significant antibody levels were found for Cyst-CA. The G and A isotypes were found but not the M isotype. A second series of experiments showed that A and G titres were elevated, depending on the type of Cyst-CA and the onset of the disease. IgG to Cyst-3,4-dihydroxyphenylalanine (L-DOPA) were present in cases of bulbar and upper limb onsets. IgA to Cyst-homovanillic acid (HVA), Cyst-adrenaline (A), and Cyst-dopamine (DA) were found in lower limb onset. These results indirectly show that: 1) the oxidation of CA and the formation of Cyst-CA may be involved in ALS; 2) these radical processes have different targets depending on the onset of the disease.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Myasthenia Gravis ll: Pathophysiology

